Fluoksetin ve Essitalopram Tedavisi Sonrası Gelişen Ekimotik Lezyonların Reboksetin Tedavisi ile Düzelmesi

Abstract

Antidepressants, frequently prescribed in depression and anxiety disorders, are known to be risk factors for an increase in bleeding. Yet, unfavourable effects of selective serotonin reuptake inhibitör (SSRI) treatment on hemostasis have rarely been reported. The most frequently reported side effects of SSRIs on the hematologic system are prolonged bleeding time, impaired thrombocyte aggregation and activity. Here we present a case in whom ecchymotic lesions occurred with esscitalopram and fluoxetine and resolved with reboxetine.

A serious dermatological side effect due to vortioxetine: a case report

“…Past studies specified the potential for DIHS alongside systemic symptoms after the use of citalopram, fluoxetine, and amitriptyline (10). While reports about ecchymosis as a result of sertraline, venlafaxine, and escitalopram are found in the literature, case reports regarding vortioxetine are limited (14)(15)(16)(17). Particularly after the use of serotonin reuptake inhibitors as antidepressants, abnormal bleeding has been reported (18).…”

Bicytopenia Associated With Paroxetine: A Case Report

“…The use of SSRIs reduces serotonin stored in platelets, decreases platelet aggregation, and increases risk of bleeding (Oyesanmi et al 1999, Halperin & Reber 2007, Sözeri-Varma et al 2012. The most common hematologic adverse effects are prolonged bleeding time, and reduced platelet aggregation and activity (Halperin & Reber 2007, Koçbıyık et al 2015). In addition, SSRIs can cause functional impairment of platelet aggregation, but not reduction in platelet number ( (Matsuura et al 2016).…”